Acurx Pharmaceuticals (ACXP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.
The mean of analysts' price targets for Acurx Pharmaceuticals (ACXP) points to a 226.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP - Get Free Report) saw a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 57,707 shares, a decline of 21.8% from the February 12th total of 73,787 shares. Currently, 2.8% of the shares of the company are short sold. Based
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.
Acurx Pharmaceuticals, Inc. ( ACXP ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Robert Shawah - Co-Founder & CFO David Luci - Co-Founder, President, CEO, Corporate Secretary & Director Conference Call Participants Matthew Keller - H.C. Wainwright & Co, LLC, Research Division James Molloy - Alliance Global Partners, Research Division Presentation Operator Greetings, and welcome to the Acurx Pharmaceuticals Third Quarter 2025 Conference Call and Business Update.
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q2 2025 Earnings Conference Call August 12, 2025 8:00 AM ET Company Participants David P. Luci - Co-Founder, President, CEO, Corporate Secretary & Director Robert G.
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Robert Shawah - Co-Founder and CFO David Luci - President and CEO Conference Call Participants Joanne Lee - Maxim Group James Molloy - Alliance Global Partners Operator Greetings and welcome to the Acurx Pharmaceuticals First Quarter 2025 Financial Results and Business Update. At this time, all participants are in a listen-only mode.